HFpEF, Aging, Inflammaging, and the Future of Anti-Inflammatory: Therapy in Heart Failure with Preserved Ejection Fraction
aging and disease · 2026
DOI: 10.14336/ad.2026.0265 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift aging and disease, 2026. Verfasst von Arkadiusz Grzeczka und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department for Basic and Preclinical Sciences, Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University in Torun, 87-100 Torun, …. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aging is the dominant risk factor for heart failure with preserved ejection fraction (HFpEF), a condition increasingly recognized as a manifestation of maladaptive cardiovascular aging. This review summarizes current evidence linking inflammaging, a chronic, low-grade inflammatory state driven by immunosenescence, mitochondrial dysfunction, and cellular senescence, to progressive myocardial fibrosis, diastolic stiffness, and HFpEF development. We discuss mechanistic pathways connecting fibroblast activation, extracellular matrix remodeling, adipose tissue-driven inflammation, and phenotype-specific inflammatory signatures, as well as the role of multimodality imaging in detecting early fibrotic and inflammatory changes. Finally, we critically evaluate emerging immunometabolic therapies, highlighting the limitations of single-cytokine blockade and the disease-modifying potential of SGLT2 inhibitors and GLP-1 receptor agonists in targeting HFpEF.
Autor:innen und Institutionen
- Department for Basic and Preclinical Sciences, Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University in Torun, 87-100 Torun, Poland.
- Charité-Universitatsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
- Working Group on Cardiovascular Magnetic Resonance, Experimental and Clinical Research Center, a Joint Cooperation Between Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany.
- DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.
- Deutsches Herzzentrum der Charité-Department of Cardiology, Angiology and Intensive Care Medicine, Berlin, Germany.
- Department of Gynecology, Berlin, Germany.
Zitieren
APA
Grzeczka, A., Graczyk, S., Gröschel, J., Spethmann, S., & Kordowitzki, P. (2026). HFpEF, Aging, Inflammaging, and the Future of Anti-Inflammatory: Therapy in Heart Failure with Preserved Ejection Fraction. aging and disease. https://doi.org/10.14336/ad.2026.0265
Vancouver
Grzeczka A, Graczyk S, Gröschel J, Spethmann S, Kordowitzki P. HFpEF, Aging, Inflammaging, and the Future of Anti-Inflammatory: Therapy in Heart Failure with Preserved Ejection Fraction. aging and disease. 2026. doi:10.14336/ad.2026.0265
BibTeX
@article{Grzeczka2026,
author = {Grzeczka, Arkadiusz and Graczyk, Szymon and Gröschel, Jan and Spethmann, Sebastian and Kordowitzki, Pawel},
title = {HFpEF, Aging, Inflammaging, and the Future of Anti-Inflammatory: Therapy in Heart Failure with Preserved Ejection Fraction},
journal = {aging and disease},
year = {2026},
doi = {10.14336/ad.2026.0265}
}
EUVIMED